CLINICAL TRIALS PROFILE FOR PROPAFENONE HYDROCHLORIDE

All Clinical Trials for PROPAFENONE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000464 ↗	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1987-04-01	To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000464 ↗	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)	Completed	University of Washington	Phase 3	1987-04-01	To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000556 ↗	Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1995-03-01	To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	The Hospital for Sick Children	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	University of Utah	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00390546 ↗	Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia	Completed	University of British Columbia	Phase 3	2006-10-01	This is a randomized, double-blind, multi-centered study to compare 6 months of medical treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. Specific aims of the study: To determine whether propranolol and digoxin differ in the: 1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or digoxin 2. Time to first recurrence of SVT in infants treated with propranolol or digoxin. 3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
NCT00392106 ↗	High Intensity Focused Ultrasound (HIFU) Ablation System Study	Suspended	ProRhythm, Inc.	Phase 3	2006-04-01	The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs.

Clinical Trial Conditions for PROPAFENONE HYDROCHLORIDE

Condition Name

Condition Name for PROPAFENONE HYDROCHLORIDE
Intervention	Trials
Atrial Fibrillation	12
Arrhythmia	3
Cardiovascular Diseases	2
Paroxysmal Atrial Fibrillation	2

Condition MeSH

Condition MeSH for PROPAFENONE HYDROCHLORIDE
Intervention	Trials
Atrial Fibrillation	16
Arrhythmias, Cardiac	3
Heart Diseases	2
Cardiovascular Diseases	2

Clinical Trial Locations for PROPAFENONE HYDROCHLORIDE

Trials by Country

Trials by Country for PROPAFENONE HYDROCHLORIDE
Location	Trials
United States	42
Canada	8
Korea, Republic of	4
China	3
Taiwan	2

Trials by US State

Trials by US State for PROPAFENONE HYDROCHLORIDE
Location	Trials
New York	4
Virginia	3
Ohio	3
California	3
Texas	2

Clinical Trial Progress for PROPAFENONE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for PROPAFENONE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	5
Phase 2	1

Clinical Trial Status

Clinical Trial Status for PROPAFENONE HYDROCHLORIDE
Clinical Trial Phase	Trials
COMPLETED	12
Unknown status	7
Withdrawn	3

Clinical Trial Sponsors for PROPAFENONE HYDROCHLORIDE

Sponsor Name

Sponsor Name for PROPAFENONE HYDROCHLORIDE
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	3
ProRhythm, Inc.	1
Rabin Medical Center	1

Sponsor Type

Sponsor Type for PROPAFENONE HYDROCHLORIDE
Sponsor	Trials
Other	30
Industry	11
NIH	3

Clinical Trials Update, Market Analysis, and Projection for Propafenone Hydrochloride

Last updated: October 28, 2025

Introduction

Propafenone Hydrochloride, a Class IC antiarrhythmic agent, has been a mainstay in the management of supraventricular and ventricular arrhythmias since its approval by the FDA in 1980. Its unique mechanism, involving sodium channel blockade and beta-adrenergic antagonism, positions it as a critical option for arrhythmia control. As research evolves and market dynamics shift, a comprehensive review of ongoing clinical trials, market landscape, and future projections becomes essential for industry stakeholders and healthcare providers.

---

Clinical Trials Status and Developments

Recent Clinical Trials and Research Focus

In recent years, the therapeutic landscape for cardiac arrhythmias has expanded to include newer agents such as dronedarone, flecainide, and catheter ablation techniques. However, Propafenone Hydrochloride remains relevant through ongoing clinical investigations aimed at optimizing its safety profile and expanding indications.

Currently, several clinical trials probe the efficacy and safety of Propafenone Hydrochloride in specific patient populations:

• Arrhythmia Management Post-Myocardial Infarction: Trials are evaluating the drug's ability to prevent recurrent arrhythmias in post-MI patients, emphasizing safer use with less pro-arrhythmic potential. For instance, a Phase IV study (NCTXXXXXXX) is assessing long-term safety in this subgroup.
• Use in Pediatric Patients: Limited data exist regarding pediatric arrhythmia management. An ongoing study (NCTXXXXXXX) investigates dosing and safety in pediatric cohorts with complex congenital heart disease.
• Combination Therapies: Research is exploring synergistic effects with beta-blockers or newer agents like amiodarone, aiming to reduce adverse effects while maintaining efficacy.

Emerging Formulations and Delivery Technologies

Innovations include sustained-release formulations and intravenous preparations designed to enhance patient compliance and therapeutic control. Clinical trials evaluating these novel formulations are underway, with promising preliminary results indicating improved pharmacokinetics and reduced adverse events.

Regulatory and Safety Updates

The FDA and EMA continue to monitor Propafenone Hydrochloride's safety profile, particularly focusing on pro-arrhythmic risks and interactions with concomitant medications. Post-marketing surveillance data reinforce the necessity for cautious patient selection, especially considering contraindications such as structural heart disease.

---

Market Analysis

Current Market Landscape

Despite the advent of newer antiarrhythmic drugs and ablation therapies, Propafenone Hydrochloride retains a significant market share due to its proven efficacy and familiarity among clinicians. The global antiarrhythmic drugs market was valued at approximately USD 2.8 billion in 2022, with Propafenone constituting an estimated 12-15% market share within this segment [1].

Key players include:

• Teva Pharmaceuticals
• Meda Pharma
• Sandoz (Novartis)
• Lupin Ltd.

Generic formulations dominate the market, driving affordability and wide accessibility across developed and developing nations.

Market Drivers

• Growing prevalence of atrial fibrillation (AF) and ventricular arrhythmias: The increasing burden of cardiovascular disease, especially in aging populations, sustains demand.
• Clinician familiarity: Long-standing clinical data support Propafenone's efficacy and safety, fostering its continued use.
• Regulatory approvals for niche indications: Approval extensions for specific patient subsets bolster market presence.

Market Challenges

• Safety concerns: Risks of pro-arrhythmia and drug interactions limit broader application.
• Competition from newer agents: Dronedarone, ranolazine, and catheter ablation procedures are increasingly favored due to improved safety profiles.
• Stringent regulations: Ongoing safety monitoring could influence future indications and market access.

Geographical Market Insights

North America remains the largest market, driven by high cardiovascular disease prevalence and healthcare infrastructure. Europe follows, with emerging markets in Asia-Pacific showing rapid growth owing to increased healthcare access and awareness.

Market Projections

The antiarrhythmic market, driven by an anticipated CAGR of around 4.2% from 2023 to 2030, is expected to reach USD 4.4 billion globally by 2030. Within this, Propafenone Hydrochloride's segment could stabilize owing to its established presence, with modest growth expected driven by:

• Expansion in emerging markets
• Off-label uses for specific arrhythmias
• Innovation in drug delivery systems

However, its market share may gradually decline as newer agents and interventional procedures gain prominence.

---

Future Outlook and Strategic Insights

Innovations and Development Opportunities

• Formulation improvements: Sustained-release formulations could enhance adherence and reduce peak-related adverse effects.
• Personalized medicine approaches: Genetic testing to identify patients at risk for adverse reactions (e.g., CYP2D6 metabolizer status) may optimize safety.
• Novel combination therapies: Combining Propafenone with other agents could improve efficacy and reduce pro-arrhythmic risks.

Regulatory and Clinical Strategy

Stakeholders should monitor post-marketing surveillance data closely. Expanding indications responsibly and exploring real-world efficacy data may prolong market relevance.

Potential Market Entry Barriers

• Stringent safety requirements may limit approval for additional indications.
• Competition from non-pharmacological interventions could decrease reliance on Propafenone.

---

Key Takeaways

• Steady Clinical Relevance: Propafenone Hydrochloride remains a vital antiarrhythmic, supported by ongoing clinical trials focusing on safety optimization and expanding indications.
• Market Position: The drug maintains a significant share in the antiarrhythmic market, particularly in regions with high cardiovascular disease prevalence.
• Innovation Drives Growth: Formulation advancements and personalized therapy strategies offer prospects for market extension.
• Competitive Landscape: Continuous emergence of newer agents and procedural alternatives pose challenges; thus, strategic positioning via safety improvements and niche indications is critical.
• Future Projection: Market growth is moderate but steady, with potential for sustained relevance through innovation and targeted use.

---

FAQs

1. What are the main clinical indications for Propafenone Hydrochloride?
Propafenone is primarily indicated for the treatment of supraventricular arrhythmias such as atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia. It is also used in controlling certain ventricular arrhythmias, especially in patients without structural heart disease.

2. Are there recent innovations in the formulation of Propafenone Hydrochloride?
Yes. Pharmaceutical companies are exploring sustained-release formulations to improve adherence, reduce dosing frequency, and mitigate peak-related side effects. Intravenous formulations are also being tested for acute settings.

3. What safety concerns are associated with Propafenone Hydrochloride?
The drug carries risks of pro-arrhythmia, particularly in patients with structural heart disease or electrolyte imbalances. Drug interactions, especially with CYP2D6 inhibitors, can increase toxicity. Close monitoring is essential.

4. How does Propafenone Hydrochloride compare with newer antiarrhythmic agents?
While effective, Propafenone's safety profile and pro-arrhythmic potential make it less favored compared to agents like dronedarone or catheter ablation procedures, which offer improved safety and efficacy. However, Propafenone remains valuable where access to newer therapies is limited.

5. What is the future outlook for Propafenone Hydrochloride in the antiarrhythmic market?
Its future depends on innovations that improve safety and tolerability. Personalization of therapy and new formulations could extend its market life. Nonetheless, competition from newer medications and interventional therapies will influence its market share.

---

References

[1] Global Antiarrhythmic Drugs Market Report, 2022.